Thursday, June 13, 2024
Volume 2, Issue 2

Clinical Spotlight

MAJESTEC-1 Update

MAJESTEC-1 Update

The MAJESTEC-1 study was presented at ASCO, and appeared concomitantly in the New England Journal of Medicine. In this phase...

MAJESTEC-1 Update

DETERMINATION Study

Prof Paul Richardson presented the DETERMINATIION trial at both ASCO and EHA, and the manuscript appeared at the same time...

T-cell Redirecting Therapies for Multiple Myeloma Treatment

CASSIOPEIA Maintenance

Lancet Oncology recently published a study on the CASSIOPEIA study, which is a two-part, open-label, randomized, phase 3 trial of patients...

HOVON 143 Study

HOVON 143 Study

An interesting study for the frail myeloma patients who are not eligible for ASCT is the phase II, Hovon 143...

Treatment of new diagnosed Myeloma patients

MAIA Study

Recently, Lancet Oncology published an update of the MAIA study regarding overall survival (OS). MAIA is an ongoing, multicenter, randomized, open-label,...

Clinical Research

Clinical Research

During the last 3 months, the results of two important phase-3 studies, using anti-CD38 monoclonal antibodies for the treatment of...

Sign Up to Our Newsletter